Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cervical Squamous Cell Carcinoma: early-phase trial registry
4 of 14 indexed Cervical Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 4 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Cervical Squamous Cell Carcinoma: 14 US clinical trials tracked, 4 recruiting.
Cervical Squamous Cell Carcinoma is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition cervical-squamous-cell-carcinoma
OPEN 4 | RECR 29% | LATE 2 | EARLY 11 | RANK #1230 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Acne Scars (29% recruiting · 7 trials)
Cervical Squamous Cell Carcinoma lists 4 open slots (29% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cervical Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cervical Squamous Cell Carcinoma is recruiting below its size-band peers.
4 of 14 indexed trials (28.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Cervical Squamous Cell Carcinoma research.
National Cancer Institute (NCI) accounts for 5 of 14 trials (35.7%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Cervical Squamous Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 64 among the 14 trials that report a genuine target (sentinel values excluded). 9 of those (64.3%) plan for fewer than 100 participants.
-
Cervical Squamous Cell Carcinoma research is mostly interventional.
14 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Alentis Therapeutics
NCT07169734
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Alentis Therapeutics
NCT06747585
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United
NCT07217171
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Jonsson Comprehensive Cancer Center
NCT06543576
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
National Cancer Institute (NCI)
NCT02466971
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
GOG Foundation
NCT01649089
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Boundless Bio
NCT05827614
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
Gynecologic Oncology Group
NCT00104910
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
National Cancer Institute (NCI)
NCT00031993
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
National Cancer Institute (NCI)
NCT00025233
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
Gynecologic Oncology Group
NCT00309959
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
National Cancer Institute (NCI)
NCT00057863
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
M.D. Anderson Cancer Center
NCT01365156
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
National Cancer Institute (NCI)
NCT01266447
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 5 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Cervical Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cervical Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cervical Squamous Cell Carcinoma page
14 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Cervical Squamous Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Cervical Squamous Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cervical Squamous Cell Carcinoma condition card totals 14 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.